Latest Breaking News On - Leukaemia initiating cells - Page 1 : comparemela.com

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said its Bi-Cygni antibody-drug conjugate, BVX001, has shown a 126% increase in survival rates in a.

Bivictrix therapeuticsLeukaemia initiating cellsLeukaemia stem cells